Bristol-Myers Squibb 8-K

Summary

Investor presentation outlining Bristol Myers Squibb’s growth strategy and pipeline. The company highlighted 2025 Growth Portfolio momentum, strategic business development and pipeline progress as the foundation for sustainable growth into the 2030s. It expects 10+ potential product launch opportunities by 2030, contingent on successful trials and regulatory approvals.

Key Figures

• Growth Portfolio sales rose 17% for the nine months ended 9/30/2025 vs the same period in 2024; four assets had annualized worldwide sales above $1B, based on Q3 2025 revenue.
• Over the past three years, the company returned approximately $14.5B through dividends and approximately $8B through share repurchases.
• The presentation lists 2026 registrational data expected for admilparant in idiopathic pulmonary fibrosis, arlo-cel in multiple myeloma, iberdomide and mezigdomide in multiple myeloma, milvexian in atrial fibrillation and secondary stroke prevention, and RYZ101 in gastroenteropancreatic neuroendocrine tumors.

Investor Takeaways

• 2026 registrational and life-cycle-management data—including Cobenfy studies in Alzheimer’s disease psychosis and Sotyktu studies in systemic lupus erythematosus—will test the pipeline’s near-term potential.
• Progress toward the 10+ potential launches by 2030 depends on clinical results and regulatory approvals.